Akcea Therapeutics (AKCA) Reaches $20.29 After 4.00% Down Move; Kynikos Associates LP Cut By $464,468 Its Schlumberger LTD (SLB) Position

August 31, 2017 - By Louis Casey

Kynikos Associates Lp decreased Schlumberger Ltd (SLB) stake by 13.48% reported in 2016Q4 SEC filing. Kynikos Associates Lp sold 5,596 shares as Schlumberger Ltd (SLB)’s stock declined 11.04%. The Kynikos Associates Lp holds 35,930 shares with $3.02 million value, down from 41,526 last quarter. Schlumberger Ltd now has $87.94 billion valuation. The stock rose 0.24% or $0.15 reaching $63.52. About 1.90M shares traded. Schlumberger Limited. (NYSE:SLB) has declined 3.30% since August 31, 2016 and is downtrending. It has underperformed by 20.00% the S&P500.

The stock of Akcea Therapeutics Inc (NASDAQ:AKCA) is a huge mover today! About 248,257 shares traded. Akcea Therapeutics Inc (NASDAQ:AKCA) has 0.00% since August 31, 2016 and is . It has underperformed by 16.70% the S&P500.The move comes after 6 months negative chart setup for the $1.35 billion company. It was reported on Aug, 31 by Barchart.com. We have $19.48 PT which if reached, will make NASDAQ:AKCA worth $54.00M less.

Since March 1, 2017, it had 1 buy, and 2 selling transactions for $2.87 million activity. CURRIE PETER L S also bought $250,203 worth of Schlumberger Limited. (NYSE:SLB) on Tuesday, May 30. $407,700 worth of stock was sold by SANDVOLD TORE I on Wednesday, March 1. Floridia Aaron Gatt also sold $2.77M worth of Schlumberger Limited. (NYSE:SLB) shares.

Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.29, from 1.17 in 2016Q3. It is negative, as 65 investors sold SLB shares while 567 reduced holdings. 118 funds opened positions while 550 raised stakes. 1.08 billion shares or 1.19% more from 1.07 billion shares in 2016Q3 were reported. Segall Bryant & Hamill Lc reported 694,327 shares stake. 97,574 are owned by Biondo Invest Advisors Ltd Liability Corporation. Hayek Kallen Mngmt holds 1.25% or 20,492 shares. Salient Lta invested in 128,060 shares. Creative Planning holds 0.04% of its portfolio in Schlumberger Limited. (NYSE:SLB) for 73,586 shares. Mitsubishi Ufj Securities Limited holds 200 shares or 0.1% of its portfolio. Tower Cap Ltd Llc (Trc) has 36,984 shares for 0.34% of their portfolio. Kanawha Capital Mngmt reported 0.87% of its portfolio in Schlumberger Limited. (NYSE:SLB). Strategic Services Inc owns 0.78% invested in Schlumberger Limited. (NYSE:SLB) for 48,234 shares. First Reserve Grp Xii Ltd holds 49.87% or 2.07M shares. Pnc Fincl Grp has invested 0.39% in Schlumberger Limited. (NYSE:SLB). Quantitative Management Limited Com reported 0.23% in Schlumberger Limited. (NYSE:SLB). Sphera Funds Mngmt Ltd owns 34,361 shares for 0.73% of their portfolio. Train Babcock Advsrs Ltd reported 2.24% in Schlumberger Limited. (NYSE:SLB). 4,110 are held by Invest House Ltd Limited Liability Company.

Kynikos Associates Lp increased Spdr S&P Midcap 400 Etf Tr (MDY) stake by 228,274 shares to 229,036 valued at $69.11M in 2016Q4. It also upped Powershares Qqq Trust (QQQ) stake by 63,382 shares and now owns 65,308 shares. United States Natl Gas Fund (UNG) was raised too.

Among 33 analysts covering Schlumberger Limited. (NYSE:SLB), 26 have Buy rating, 1 Sell and 6 Hold. Therefore 79% are positive. Schlumberger Limited. had 102 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of Schlumberger Limited. (NYSE:SLB) has “Neutral” rating given on Tuesday, May 10 by Guggenheim. On Tuesday, June 27 the stock rating was downgraded by Atlantic Securities to “Neutral”. Barclays Capital upgraded Schlumberger Limited. (NYSE:SLB) on Wednesday, April 20 to “Overweight” rating. The stock of Schlumberger Limited. (NYSE:SLB) has “Buy” rating given on Tuesday, July 19 by Societe Generale. The stock of Schlumberger Limited. (NYSE:SLB) earned “Outperform” rating by Credit Suisse on Monday, April 4. The firm has “Buy” rating given on Wednesday, October 5 by Citigroup. On Thursday, September 3 the stock rating was upgraded by Citigroup to “Buy”. The rating was maintained by Morgan Stanley on Tuesday, April 19 with “Overweight”. Barclays Capital maintained the shares of SLB in report on Monday, January 25 with “Equal Weight” rating. The firm has “Buy” rating given on Monday, October 5 by Citigroup.

Among 2 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc has $2500 highest and $1900 lowest target. $22’s average target is 8.43% above currents $20.29 stock price. Akcea Therapeutics Inc had 2 analyst reports since August 8, 2017 according to SRatingsIntel. The rating was initiated by BMO Capital Markets with “Buy” on Tuesday, August 8. Stifel Nicolaus initiated the stock with “Buy” rating in Tuesday, August 8 report.

Akcea Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $1.35 billion. The Firm is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It currently has negative earnings. The Company’s drugs, volanesorsen, AKCEA-APO-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis).